Shanghai Junshi Biosciences Co., Ltd. (OTCMKTS:SHJBF – Get Free Report) saw a large decline in short interest in September. As of September 30th, there was short interest totaling 200 shares, a decline of 80.0% from the September 15th total of 1,000 shares. Based on an average daily volume of 0 shares, the short-interest ratio is presently ∞ days.
Shanghai Junshi Biosciences Stock Performance
SHJBF stock opened at C$3.35 on Tuesday. Shanghai Junshi Biosciences has a 1-year low of C$2.99 and a 1-year high of C$4.23. The business has a 50 day simple moving average of C$3.35 and a two-hundred day simple moving average of C$3.27.
Shanghai Junshi Biosciences Company Profile
Shanghai Junshi Biosciences Co, Ltd. is a China-based biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative medicines. Its research activities cover oncology, autoimmune and inflammatory diseases, metabolic disorders, infectious diseases and other therapeutic areas, with programs based on monoclonal antibodies, small-molecule medicines and other biotechnology platforms.
The company’s best-known product is toripalimab, an anti-PD-1 monoclonal antibody marketed in China under the brand name Tuoyi.
See Also
- Five stocks we like better than Shanghai Junshi Biosciences
- Delta’s Guidance Cut Could Spell Trouble for the Airline Industry
- Salesforce Just Got a Rare Double Upgrade—What Changed?
- OpenAI’s Revenue Scare Could Be a Big Opportunity for Investors
- China Still Dominates Rare Earths—These 3 U.S. Companies Could Benefit
Receive News & Ratings for Shanghai Junshi Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shanghai Junshi Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
